Key result
The 2020 AHA/ACC guidelines expanded indications for invasive treatments like septal myectomy and alcohol septal ablation for symptomatic patients with left ventricular outflow tract obstruction.
This review summarizes key updates in the 2020 AHA/ACC guidelines for hypertrophic cardiomyopathy, emphasizing expanded roles for invasive septal reduction therapies and updated management of arrhythmias and heart failure.
Answers are grounded in this paper and cite their sources.
Guidelines expand invasive options for symptomatic obstructive HCM; leaves open need for prospective outcome data before broad adoption.
On 22 December 2020, Circulation published the new American College of Cardiology / American Heart Association guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. The most important guidelines were those concerning pharmacological and invasive methods of treating symptomatic patients with obstruction of the left ventricular outlet. Considering the most recent clinical studies, the indications for invasive methods of treatment have expanded to include septal myectomy and alcohol septal ablation. A separate section in the guidelines has been devoted to the management of non-obstructive hypertrophic cardiomyopathy with preserved left ventricular ejection fraction. The recommendations for patients with hypertrophic cardiomyopathy with atrial fibrillation, ventricular arrhythmias and severe heart failure have been revised.
No takes yet. Share an insight, caveat, or question.
Budagaev et al. (2021) conducted a review in Hypertrophic cardiomyopathy. 2020 AHA/ACC guidelines was evaluated. The 2020 AHA/ACC guidelines expanded indications for invasive treatments like septal myectomy and alcohol septal ablation for symptomatic patients with left ventricular outflow tract obstruction.
Synapse has enriched 10 related papers. Consider them for comparative context: